ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Board Meeting to be held on 27-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend.

AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

AstraZeneca pharmaceuticals ABï¿‚ï¾ has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaï¿‚ï¾ (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.ï¿‚ï¾

AstraZeneca Pharma India Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has informed the Exchange regarding voting results along with copy of scrutinizers report.

Significant increase in volume has been observed in AstraZeneca Pharma India Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. AstraZeneca Pharma India Limited has submitted their response.

Significant increase in volume has been observed in AstraZeneca Pharma India Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

AstraZeneca Pharma India Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015'.

AstraZeneca Pharma India Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Appointment of Senior Management Personnel'.

AstraZeneca Pharma India Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015'.

AstraZeneca Pharma India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Closure of Trading Window

AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Loss of share certificates

AstraZeneca Pharma India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Closure of Trading Window

AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

AstraZeneca Pharma India Limited has informed the Exchange about Loss of Share Certificates

ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Loss of share certificates

AstraZeneca Pharma India Limited has informed the Exchange regarding a press release dated March 11, 2024, titled "Intimation about Distribution and Promotion Agreement between AstraZeneca Pharma India Limited ("Company") and Mankind Pharma Limited for innovative budesonide and formoterol fumarate dihydrate (Symbicort)".